 Today, I have the pleasure of speaking with Dr. Horst Aserb. How are you today? I'm great. How about yourself? I am absolutely fascinated by your background. I read that you hold over 40 patents in drug delivery-related fields. You've published numerous scientific papers, but for some reason you've decided to start a publicly listed company in 2003 called Intel Janix. Tell us why. Well, I simply saw an opportunity for myself as a research scientist in the pharmaceutical field to get engaged in the area of oral drug delivery, which has been my background for many, many years. And when I saw that opportunity, I just grabbed it, if you will. It was really as simple as that. But it doesn't sound simple to me, especially with all these scientific research papers specifically on this oral film drug delivery. And I read that you are the gentleman who came up with the Listerine Oral Films. Is that correct? Well, I am the co-inventor of the Listerine technology. And I've since been involved, actually even before I started Intel Janix, in many of those oral film development programs. And can you tell me why oral films? Why not, you know, everybody's putting gummy bears or lotions. Why oral films? What are the benefits? What are the real advantages of this? It's a very good question. Oral films have a number of advantages. As scientists that are active in drug delivery, we mostly want to improve the appearance of a drug in the bloodstream. So in other words, in our language, we want to improve the bioavailability of a drug. And secondly, but equally importantly, we want to provide tangible therapeutic benefits to a patient. And the combination of those two then led to the development of oral films as a delivery platform. So one of some of these benefits besides improvement of bioavailability would be that you would be able, for example, to replace an injectable with an oral product. Nobody likes the needle and, you know, practically everybody would prefer an oral product over a needle. There are special needs, patient populations like small children or elderly people who have problems swallowing tablets. For those patient populations, the film would be an event, and there are few other of these advantages that come with the film delivery system. Well, I can tell you, I am certainly one of many that does not enjoy a needle. So can you tell me about this drug repurposing, though, until GenX really has a commitment to drug repurposing. And I did a little bit of research on this. Can you just give us kind of a 10-story view from what you're trying to do? Yeah, repurposing is an area that we have been focusing on for quite some time now. And it sort of determines our strategic focus for the foreseeable future. Essentially what you do in drug repurposing is you take an FDA approved drug, a drug that is approved for some indication, and then in the case that or in a situation that research finds out that the drug might be beneficial for a different indication, you then put in the work required to qualify the drug in the eyes of FDA for this new indication. To give you an example, we're right now working on a product that has been for many, many years approved for the treatment of asthma. We found or a researcher that we are cooperating with very closely found that this drug might be very beneficial in the treatment of certain cognitive disorders, Alzheimer's in its strongest form, mild cognitive impairment, things like that. Practically every person over 55, 60 suffers from some form of cognitive impairment and currently there is no treatment available to really treat this disease or situation that affects so many elderly people. That is really what drug repurposing does. You take an approved drug and qualify it for a new indication. The advantage of doing that is that you do not have to provide to provide all the safety data that FDA requires for a completely new chemical entity because that has already been done in the course of qualifying that drug for its initial indication. All these rats and mice tests that take many years and that go into the qualification of a completely new chemical entity, you don't have to do that for a drug repurposing situation. Let me understand because this really touches my heart. I think all of us have been directly affected by elders in our family with Alzheimer's and dementia. You're stating that the repurposing of some of these drugs may actually be used to maybe reduce the speed in which they inflict patients, is that correct? Not only that, there is evidence, however not yet in humans so far only in animal models, that suggests that this molecule might actually rejuvenate the brain. Okay, well I'm definitely interested in hearing more about rejuvenating the brain, specifically these Montalucast. Can you tell me why Montalucast? Montalucast is that drug that I was just describing. Montalucast has been used for decades by patients for the treatment of asthma and researchers have now found that the drug has the potential to rejuvenate the brain. Thank you so much for joining us today, Dr. Zerb. It's my pleasure, thank you very much for having me.